Promising Results Suggest a Larger Role for Immunotherapy in TNBC

Jason Harris
Published: Saturday, Feb 01, 2020
Dr. Leisha A. Emens, a professor of medicine in hematology/oncology, co-leader of the Hillman Cancer Immunology Program, director of translational immunotherapy for the Women's Cancer Research Center at UPMC Hillman Cancer Center

Leisha A. Emens, MD, PhD

Although most breast tumors are not immunogenic, evidence indicates that triple-negative breast cancer (TNBC) expressing PD-L1 is a strong candidate for immunotherapy, explained Leisha A. Emens, MD, PhD, in a presentation on recent trials of immunotherapy alone and in combination with anti–PD-1 therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication